Table 2 Annual changes in disease activity indices and serum MMP-3 levels
From: MMP-3 as a predictor for structural remission in RA patients treated with MTX monotherapy
| Â | 0Â year | 1Â year | 2Â years | 3Â years | Number of patients |
|---|---|---|---|---|---|
DAS28-ESR(4) | 5.5 ± 1.2 | 4.1 ± 1.3*** | 3.8 ± 1.3*** | 3.6 ± 1.4*** | 129 |
DAS28-CRP(4) | 4.8 ± 1.1 | 3.4 ± 1.2*** | 3.1 ± 1.2*** | 2.6 ± 1.3*** | 129 |
DAS28-ESR(3) | 5.2 ± 1.1 | 4.2 ± 1.3*** | 4.0 ± 1.23*** | 3.9 ± 1.4*** | 161 |
DAS28-CRP(3) | 4.5 ± 1.0 | 3.5 ± 1.2*** | 3.2 ± 1.2*** | 3.1 ± 1.3*** | 161 |
mHAQ | 0.541 ± 0.470 | 0.269 ± 0.388*** | 0.205 ± 0.318*** | 0.180 ± 0.323*** | 129 |
MMP3, ng/ml | 241.9 ± 304.2 | 178.5 ± 287.8** | 174.7 ± 299.5*** | 181.5 ± 321.2*** | 157 |